Prostate Cell News Volume 10.13 | Apr 12 2019

TOP STORY

Spatially Restricted Stromal Wnt Signaling Restrains Prostate Epithelial Progenitor Growth through Direct and Indirect Mechanisms

Researchers showed that stromal cells in the proximal prostatic duct near the urethra, a mouse prostate stem cell niche, not only produce multiple Wnt ligands but also exhibited strong Wnt/β-catenin activity. [Cell Stem Cell] Abstract | Graphical Abstract

(Ranked by impact factor of the journal)

BRCA1 and EZH2 Cooperate in Regulation of Prostate Cancer Stem Cell Phenotype

Investigators demonstrated that BRCA1 and enhancer of zeste homolog 2 (EZH2) are co‐regulated in patients’ tumors and prostate cancer cell lines and cooperated in the regulation of the CSC phenotype and properties. Knockdown of BRCA1 expression significantly increased the number and the size of tumor spheres. [Int J Cancer] Abstract

Immunoreactivity for Prostate Specific Antigen and Ki67 Differentiates Subgroups of Prostate Cancer Related to Outcome

Patients with prostate specific antigen low/Ki67 high tumors showed higher Gleason score, more advanced tumor stage, and higher risk of prostate cancer death compared to other patients. Their tumor epithelial cells were often ERG positive and expressed higher levels of ErbB2, phosphorylated epidermal growth factor receptor and protein kinase B, and their tumor stroma showed a reactive response with type 2 macrophage infiltration, high density of blood vessels and hyaluronic acid, and with reduced levels of caveolin-1, androgen receptors, and mast cells. [Mod Pathol] Full Article

Prostate Cancer Cells Hyper-Activate CXCR6 Signaling by Cleaving CXCL16 to Overcome Effect of Docetaxel

Treatment of prostate cancer cells with anti-CXCR6 monoclonal antibody synergistically or additively induced cell death with ∼1.5-4.5 fold reduction in the effective concentration of DTX. [Cancer Lett] Abstract

High-Throughput, Time-Resolved Mechanical Phenotyping of Prostate Cancer Cells

The authors demonstrated the discrimination of healthy and cancerous prostate cell lines based on the whole-cell, time-resolved mechanical response to a hydrodynamic load. [Sci Rep] Full Article

High Skp2 Expression Is Associated with a Mesenchymal Phenotype and Increased Tumorigenic Potential of Prostate Cancer Cells

Researchers investigated the expression and localization of Skp2 in clinical samples from patients with prostate cancer, the association of Skp2 with epithelial-to-mesenchymal transition status, and the role of Skp2 in prostate cancer stem cells. [Sci Rep] Full Article

ZFHX3 Is Indispensable for ERβ to Inhibit Cell Proliferation via MYC Downregulation in Prostate Cancer Cells

Scientists investigated whether zinc-finger homeobox 3 (ZFHX3) and estrogen receptor β (ERβ) functionally interacted with each other in the suppression of prostatic tumorigenesis. In two androgen receptor-positive prostate cancer cell lines, C4-2B and LNCaP, they validated ERβ’s tumor suppressor activity indicated by the inhibition of cell proliferation and repression of MYC expression. [Oncogenesis] Full Article

Downregulation of CENPF Remodels Prostate Cancer Cells and Alters Cellular Metabolism

The authors focused on discerning the role of centromere protein F (CENPF) in metabolic perturbation in human PC3 cells. A series of bioinformatics analyses showed that CENPF is one gene that is strongly associated with aggressive prostate cancer, and that its expression is positively correlated with metastasis. [Proteomics] Abstract

miR‐103a‐2‐5p/miR‐30c‐1‐3p Inhibits the Progression of Prostate Cancer Resistance to Androgen Ablation Therapy via Targeting Androgen Receptor Variant 7

Investigators revealed that the messenger RNA expression and the protein levels of an androgen receptor (AR) variant 7 were higher in prostate cancer tissue samples and in the AR‐positive prostate cancer cell line, VCaP. [J Cell Biochem] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Metabolomic Profiling for the Identification of Novel Diagnostic Markers in Prostate Cancer: An Update

The authors provide an updated review of the current understanding of the prostate cancer metabolome and evaluate the possibility of unveiling novel therapeutic targets. [Expert Rev Mol Diagn] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Project Data Sphere Builds on Five Years of Success by Expanding Open-Access Data Platform and Broadening Research Programs that Accelerate New Cancer Patient Therapies

Today, with 150 datasets representing more than 100,000 patient lives and with 21 peer-reviewed publications derived from that data, Project Data Sphere, LLC is expanding the capabilities of the platform to integrate the power of machine learning and artificial intelligence. [Project Data Sphere, LLC (Business Wire, Inc.)] Press Release

Precision Therapeutics’ Subsidiary, Helomics^® Corporation, and SpeciCare, Inc. to Study Innovative Personalized Medicine Opportunities for Cancer Patients

Precision Therapeutics Inc. announced that its wholly-owned subsidiary, Helomics^® Corporation and SpeciCare have signed an agreement for Helomics to provide CRO services and its D-CHIP artificial intelligence platform for a functional precision medicine study sponsored by SpeciCare. [Precision Therapeutics Inc.] Press Release

Impact Factors Are Still Widely Used in Academic Evaluations

About 40% of institutes with a strong focus on research mention impact factors in documents used in the review, promotion and tenure process, according to the analysis, which examined more than 800 documents across 129 institutions in the United States and Canada. [Nature News] Editorial

FDA, New York Attorney General Go After Stem Cell Clinics

On April 3, the FDA sent letters to 20 companies providing stem cell treatments, reports The New York Times, reminding them that they may require FDA approval and should take action to comply. The agency also issued a warning to a stem cell company for violating good manufacturing practices. [The Scientist] Editorial

NEW Global Congress on Prostate Cancer
October 23-24, 2019
Paris, France

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Cancer Systems Imaging (The University of Texas MD Anderson Cancer Center)

Research Assistant – Prostate Cancer Biology (University of Oxford)

Research Fellow – Bioinformatics (University College London)

Postdoctoral Fellow and PhD Student Position – Hormone Driven Cancer (Institute of Oncology Research)

Postdoctoral Position – Prostate Cancer (UT Health San Antonio)

Postdoctoral Position – Microenvironment & Cancer (Brigham and Women’s Hospital)

Faculty Position – Prostate Cancer Biology and Cancer Epigenetics (Northwestern University Feinberg School of Medicine)

Senior Computational Biologist – Molecular Oncology (Cancer Research UK Manchester Institute)

Postdoctoral Fellow – Prostate Cancer & Stem Cell Biology (City of Hope)

Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.